Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
24.23 (1y: +18%)
Market Cap 37.97 B P/E(ttm) 38.20
Enterprise Value 39.13 B P/B 1.38
TKPYY- OTCPK (USA)
Takeda Pharmaceutical Co., Ltd.
  • Currently 2.5/5
Business Predictability Rank: 2.5-Star (On Watch)
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$24.23
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 1.433
TKPYY's Cash to Debt is ranked lower than
66% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. TKPYY: 1.433 )
TKPYY' s 10-Year Cash to Debt Range
Min: 1.43   Max: No Debt
Current: 1.43
Equity to Asset 0.366
TKPYY's Equity to Asset is ranked lower than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. TKPYY: 0.366 )
TKPYY' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.81
Current: 0.37
0.37
0.81
Interest Coverage No Debt
TKPYY's Interest Coverage is ranked lower than
68% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. TKPYY: No Debt )
TKPYY' s 10-Year Interest Coverage Range
Min: 144   Max: No Debt
Current: No Debt
Z-Score: 5.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) 17.60
TKPYY's Operating margin (%) is ranked higher than
63% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. TKPYY: 17.60 )
TKPYY' s 10-Year Operating margin (%) Range
Min: 17.6   Max: 35.1
Current: 17.6
17.6
35.1
Net-margin (%) 8.2
TKPYY's Net-margin (%) is ranked higher than
61% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. TKPYY: 8.2 )
TKPYY' s 10-Year Net-margin (%) Range
Min: 8.2   Max: 26.3
Current: 8.2
8.2
26.3
ROE (%) 4.4
TKPYY's ROE (%) is ranked higher than
51% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. TKPYY: 4.4 )
TKPYY' s 10-Year ROE (%) Range
Min: 4.4   Max: 17.3
Current: 4.4
4.4
17.3
ROA (%) 3.5
TKPYY's ROA (%) is ranked higher than
50% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. TKPYY: 3.5 )
TKPYY' s 10-Year ROA (%) Range
Min: 3.5   Max: 13.2
Current: 3.5
3.5
13.2
ROC (Joel Greenblatt) (%) 47.30
TKPYY's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. TKPYY: 47.30 )
TKPYY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 47.3   Max: 171.2
Current: 47.3
47.3
171.2
Revenue Growth (%) 0.1
TKPYY's Revenue Growth (%) is ranked higher than
79% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. TKPYY: 0.1 )
TKPYY' s 10-Year Revenue Growth (%) Range
Min: 0.1   Max: 8.6
Current: 0.1
0.1
8.6
EPS Growth (%) -14.2
TKPYY's EPS Growth (%) is ranked higher than
63% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. TKPYY: -14.2 )
TKPYY' s 10-Year EPS Growth (%) Range
Min: -14.2   Max: 22.7
Current: -14.2
-14.2
22.7
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TKPYY Guru Trades in

TKPYY Guru Trades in

TKPYY Guru Trades in

Q3 2012

TKPYY Guru Trades in Q3 2012

Vanguard Health Care Fund 5,599,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TKPYY



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/E(ttm) 38.20
TKPYY's P/E(ttm) is ranked lower than
79% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.76 vs. TKPYY: 38.20 )
TKPYY' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 41.77
Current: 38.2
10.19
41.77
P/B 1.38
TKPYY's P/B is ranked higher than
71% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TKPYY: 1.38 )
TKPYY' s 10-Year P/B Range
Min: 0.91   Max: 1.37
Current: 1.38
0.91
1.37
P/S 2.49
TKPYY's P/S is ranked higher than
52% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. TKPYY: 2.49 )
TKPYY' s 10-Year P/S Range
Min: 1.67   Max: 2.72
Current: 2.49
1.67
2.72
PFCF 14.28
TKPYY's PFCF is ranked higher than
81% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. TKPYY: 14.28 )
TKPYY' s 10-Year PFCF Range
Min: 8.85   Max: 15.84
Current: 14.28
8.85
15.84
EV-to-EBIT 26.8
TKPYY's EV-to-EBIT is ranked lower than
76% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. TKPYY: 26.8 )
TKPYY' s 10-Year EV-to-EBIT Range
Min: 5.4   Max: 29.2
Current: 26.8
5.4
29.2
PEG 38.2
TKPYY's PEG is ranked lower than
81% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. TKPYY: 38.2 )
TKPYY' s 10-Year PEG Range
Min: 0   Max: 45
Current: 38.2
0
45

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 4.58
TKPYY's Dividend Yield is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. TKPYY: 4.58 )
TKPYY' s 10-Year Dividend Yield Range
Min: 2.99   Max: 5.24
Current: 4.58
2.99
5.24
Dividend Payout 1.4
TKPYY's Dividend Payout is ranked higher than
63% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.86 vs. TKPYY: 1.4 )
TKPYY' s 10-Year Dividend Payout Range
Min: 0.45   Max: 1.03
Current: 1.4
0.45
1.03
Dividend growth (3y) -2.1
TKPYY's Dividend growth (3y) is ranked higher than
89% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -0.95 vs. TKPYY: -2.1 )
TKPYY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -2.1
Current: -2.1
Yield on cost (5-Year) 4.60
TKPYY's Yield on cost (5-Year) is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. TKPYY: 4.60 )
TKPYY' s 10-Year Yield on cost (5-Year) Range
Min: 2.99   Max: 5.24
Current: 4.6
2.99
5.24
Share Buyback Rate 0.6
TKPYY's Share Buyback Rate is ranked higher than
92% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.00 vs. TKPYY: 0.6 )
TKPYY' s 10-Year Share Buyback Rate Range
Min: 2.4   Max: -0.1
Current: 0.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 11
TKPYY's Price/Net Current Asset Value is ranked lower than
77% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. TKPYY: 11 )
TKPYY' s 10-Year Price/Net Current Asset Value Range
Min: 8.1   Max: 26.9
Current: 11
8.1
26.9
Price/Tangible Book 3
TKPYY's Price/Tangible Book is ranked lower than
85% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. TKPYY: 3 )
TKPYY' s 10-Year Price/Tangible Book Range
Min: 1.7   Max: 4.4
Current: 3
1.7
4.4
Price/Median PS Value 1.4
TKPYY's Price/Median PS Value is ranked lower than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.70 vs. TKPYY: 1.4 )
TKPYY' s 10-Year Price/Median PS Value Range
Min: 1   Max: 1.1
Current: 1.4
1
1.1
Price/Graham Number 2
TKPYY's Price/Graham Number is ranked lower than
96% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. TKPYY: 2 )
TKPYY' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 2.7
Current: 2
0.9
2.7
Earnings Yield (Greenblatt) 3.70
TKPYY's Earnings Yield (Greenblatt) is ranked lower than
96% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. TKPYY: 3.70 )
TKPYY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.4   Max: 18.6
Current: 3.7
3.4
18.6

Business Description

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is hea
Company Website
Industry: Drug Manufacturers - Specialty & Generic
Compare:
Traded in other countries:4502.Japan, 4502.Japan, TKD.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial